Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | LTK | P29376 | 1/20 | 0.40 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4517546 | 0.90 | EPHX2 (0.51) | EPHX2P2RX7FFAR1HSD11B1 | |
| SCHEMBL14365321 | 0.90 | EPHX2 (0.51) | EPHX2P2RX7FFAR1HSD11B1 | |
| SCHEMBL2995839 | 0.87 | P2RX7 (0.44) | EPHX2P2RX7FFAR1HSD11B1 | |
| SCHEMBL2996038 | 0.87 | P2RX7 (0.44) | EPHX2P2RX7FFAR1HSD11B1 | |
| SCHEMBL2990514 | 0.87 | P2RX7 (0.44) | EPHX2P2RX7FFAR1HSD11B1 | |
| SCHEMBL4523656 | 0.87 | P2RX7 (0.46) | EPHX2P2RX7 | |
| SCHEMBL2992277 | 0.85 | P2RX7 (0.43) | EPHX2P2RX7FFAR1HSD11B1 | |
| SCHEMBL2996004 | 0.85 | P2RX7 (0.43) | EPHX2P2RX7FFAR1HSD11B1 | |
| SCHEMBL3000826 | 0.84 | HSD11B1 (0.56) | EPHX2P2RX7FFAR1HSD11B1 | |
| SCHEMBL2991795 | 0.84 | HSD11B1 (0.56) | EPHX2P2RX7FFAR1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | EPHX2 670/4885P2RX7 3946/4885FFAR1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.